Sino Medical Sciences Technology Inc.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Sano Medical Science and Technology Co., Ltd. was established in Tianjin Economic and Technological Development Zone in 2007, with a registered capital of 410 million yuan. It has wholly-owned subsidiaries in Beijing, Suzhou, Hong Kong, the United States, Japan, the Netherlands, and France. In October 2019, the company landed on the Shanghai Stock Exchange and became a listed enterprise on the Science and Technology Innovation Board (stock code 688108. SH). After more than ten years of development, Sano Medical has initially established an international level research and development, production, and operation system, covering key areas of interventional therapy such as cardiovascular, cerebrovascular, and structural heart disease. We have 8 key technologies and 18 product pipelines; 199 patent authorizations and exclusive licenses worldwide; The clinical research results of the company's products have been published in 24 domestic and international core journals, including 18 international core journals; Undertake 7 national and provincial-level scientific research projects, including 1 national key research and development plan project during the 13th Five Year Plan period. Since its establishment, Sano Medical's main products, including coronary drug stents, coronary balloons, and intracranial rapid exchange balloons, have been used in over 1.2 million hospitals, benefiting hundreds of thousands of patients in China, Southeast Asia, and South America. HTSupreme is the first heart stent product in China to conduct pre market clinical research on stents simultaneously in China, the United States, Japan, and Europe, and to apply for product patents in the aforementioned countries and regions. It obtained the Medical Device Registration Certificate from the National Drug Administration at the end of 2020 and was approved for product expiration extension by the National Drug Administration in November 2021. Sano Medical adheres to independent innovation, adheres to quality, and takes the path of internationalization. It is committed to promoting the development of technology in China's intervention industry, creating high-quality medical products, and enhancing the international influence of "created in China". |
| Headquarter | Tianjin |
| Establish Date | 9/21/2007 |
| Listed Code | 688108.SH |
| Listed Date | 10/30/2019 |
| Chairman | Sun Jianhua. |
| CEO | Sun Jianhua. |
| Website | www.sinomed.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
